Please be advised that due to the high volume of submissions, the ANZCTR is currently experiencing delays in processing submissions from those outside of Australia and New Zealand. As the ANZCTR is funded by Australia and New Zealand, we must prioritise submissions from these countries first. International submissions should allow additional time for registration. Apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12614001073695
Ethics application status
Approved
Date submitted
16/09/2014
Date registered
7/10/2014
Date last updated
11/05/2016
Type of registration
Retrospectively registered

Titles & IDs
Public title
A Multi-centre, Observational Study of Patients with Microangiopathic Thrombocytopenia by the Asian-Pacific Microangiopathic Thrombocytopenia (APMAT) Network
Scientific title
A Multi-centre, Observational Study by the Asian-Pacific Microangiopathic Thrombocytopenia (APMAT) Network To Determine The Clinical Characteristics, Laboratory Features, Treatments, and Clinical Outcomes in Patients with Microangiopathic Thrombocytopenia
Secondary ID [1] 285350 0
None
Universal Trial Number (UTN)
U1111-1161-8119
Trial acronym
APMAT 1
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Microangiopathic Thrombocytopenia 293074 0
Condition category
Condition code
Blood 293349 293349 0 0
Other blood disorders

Intervention/exposure
Study type
Observational
Patient registry
True
Target follow-up duration
6
Target follow-up type
Months
Description of intervention(s) / exposure
This is an observational study of previously diagnosed and treated microangiopathic thrombocytopenia (MAT) patients. MAT is a rare collection of disorders caused by the formation of intravascular aggregates of platelets resulting in microcirculatory thrombosis, red blood cell destruction and vital end-organ damage. The study will collect clinical and laboratory data to assess the disease characteristics, laboratory features, treatment strategies employed, and clinical outcome. Each participant will be observed for 6 months once they are enrolled in the study.
Intervention code [1] 290268 0
Not applicable
Comparator / control treatment
Not applicable
Control group
Uncontrolled

Outcomes
Primary outcome [1] 293183 0
To determine the clinical characteristics of microangiopathic thrombocytopenia including symptoms, potential precipitating factors, outcome, genetic, autoantibody and immune complex factors. Data will be collected by reviewing patients' medical records.
Timepoint [1] 293183 0
Follow-up of patients: 6 months;
Collection of data for all patients: Approx 18 months
Primary outcome [2] 293240 0
To determine the treatments given for microangiopathic thrombocytopenia. Data will be collected by reviewing patients' medical records.
Timepoint [2] 293240 0
Follow-up of patients: 6 months;
Collection of data for all patients: Approx 18 months
Primary outcome [3] 293241 0
To determine laboratory features microangiopathic thrombocytopenia patients. Methods for analysis include standard coagulation tests and cell counts, flow cytometry, immunoassays, activity assays and/or genotyping.
Timepoint [3] 293241 0
Follow-up of patients: 6 months;
Collection of data for all patients: Approx 18 months
Secondary outcome [1] 310539 0
To assess the value of ADAMTS13 testing in predicting disease relapse. Immunoassays and activity assays will be performed on blood samples collected at enrolment and six months post-enrolment.
Timepoint [1] 310539 0
Follow-up of patients: 6 months;
Collection of data for all patients: Approx 18 months
Secondary outcome [2] 310540 0
To assess the value of ADAMTS13 genetic mutations in predicting disease relapse. Genotyping will be performed on blood samples collected at enrolment and six months post-enrolment.
Timepoint [2] 310540 0
Follow-up of patients: 6 months;
Collection of data for all patients: Approx 18 months
Secondary outcome [3] 310541 0
To establish a MAT Biobank for further testing of novel assays used for the diagnosis and scientific understanding of MAT.
Timepoint [3] 310541 0
18 months
Secondary outcome [4] 310665 0
To facilitate basic disease mechanism and translational clinical research.
Timepoint [4] 310665 0
3 years

Eligibility
Key inclusion criteria
Patients presenting to a study centre and diagnosed with microangiopathic thrombocytopenia as defined by but not limited to anaemia, thrombocytopenia (<150 x10^9/L) and evidence of fragmented red blood cells (schistocytes) on blood film.
Minimum age
No limit
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Patients who have non-microangiopathic thrombocytopenia and/or thrombosis where an alternate diagnosis is likely.

Patients who are unable or unwilling to provide informed consent.

Study design
Purpose
Natural history
Duration
Longitudinal
Selection
Defined population
Timing
Both
Statistical methods / analysis
The sample size of this study (200) was selected to provide an observational overview of MAT patients in the APMAT Network. Interpretation of the data will be descriptive and no comparative interpretation of the data will be made. Where applicable, descriptive statistics in the form of mean (+/-SD), median and range for continuous variables and proportions (%) for categorical variables will be conducted.

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,WA,VIC
Recruitment hospital [1] 2992 0
The Alfred - Prahran
Recruitment hospital [2] 2993 0
Calvary Mater Newcastle - Waratah
Recruitment hospital [3] 2994 0
Prince of Wales Hospital - Randwick
Recruitment hospital [4] 2995 0
The Royal Adelaide Hospital - Adelaide
Recruitment hospital [5] 2996 0
Royal Prince Alfred Hospital - Camperdown
Recruitment hospital [6] 2997 0
Princess Alexandra Hospital - Woolloongabba
Recruitment hospital [7] 2998 0
Liverpool Hospital - Liverpool
Recruitment hospital [8] 2999 0
Austin Health - Austin Hospital - Heidelberg
Recruitment hospital [9] 3000 0
Royal Melbourne Hospital - City campus - Parkville
Recruitment hospital [10] 5785 0
St Vincent's Private Hospital (Darlinghurst) - Darlinghurst
Recruitment hospital [11] 5786 0
Westmead Hospital - Westmead
Recruitment hospital [12] 5787 0
Hollywood Private Hospital - Nedlands
Recruitment outside Australia
Country [1] 6356 0
China
State/province [1] 6356 0
Country [2] 6357 0
Taiwan, Province Of China
State/province [2] 6357 0
Country [3] 6358 0
Japan
State/province [3] 6358 0
Country [4] 6359 0
Korea, Republic Of
State/province [4] 6359 0
Country [5] 6360 0
Singapore
State/province [5] 6360 0
Country [6] 6361 0
Malaysia
State/province [6] 6361 0
Country [7] 6362 0
India
State/province [7] 6362 0
Country [8] 6363 0
Hong Kong
State/province [8] 6363 0
Country [9] 6364 0
Thailand
State/province [9] 6364 0
Country [10] 6365 0
New Zealand
State/province [10] 6365 0

Funding & Sponsors
Funding source category [1] 289966 0
Other Collaborative groups
Name [1] 289966 0
Australasian Society of Thrombosis and Haemostasis (ASTH)
Address [1] 289966 0
c/o PO Box 217
Glen Iris
Victoria 3146
Country [1] 289966 0
Australia
Funding source category [2] 289967 0
Commercial sector/Industry
Name [2] 289967 0
Alexion Pharmaceuticals Australasia Pty Limited
Address [2] 289967 0
Suites 226-227
117 Old Pittwater Road
Brookvale
NSW 2100
Country [2] 289967 0
Australia
Funding source category [3] 289968 0
Commercial sector/Industry
Name [3] 289968 0
BAXALTA US INC.
Address [3] 289968 0
120 Lakeside Dr
Bannockburn
IL 60015, USA
Country [3] 289968 0
United States of America
Primary sponsor type
Other Collaborative groups
Name
ASTH
Address
c/o PO Box 217
Glen Iris
Victoria 3146
Country
Australia
Secondary sponsor category [1] 288656 0
Other Collaborative groups
Name [1] 288656 0
Asia-Pacific Society on Thrombosis and Haemostasis (APSTH)
Address [1] 288656 0
c/o PO Box 217
Glen Iris
Victoria 3146
Country [1] 288656 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 291678 0
Hollywood Private Hospital Research Ethics Committee
Ethics committee address [1] 291678 0
Hollywood Private Hospital
Monash Avenue
Nedlands
WA 6009
Ethics committee country [1] 291678 0
Australia
Date submitted for ethics approval [1] 291678 0
13/05/2014
Approval date [1] 291678 0
14/08/2014
Ethics approval number [1] 291678 0
HPH383
Ethics committee name [2] 295003 0
NEAF: Hunter New England Human Research Ethics Committee
Ethics committee address [2] 295003 0
Hunter New England Research Support and Development Office
Locked Bag No.1
New Lambton NSW 2305
Ethics committee country [2] 295003 0
Australia
Date submitted for ethics approval [2] 295003 0
17/07/2015
Approval date [2] 295003 0
25/02/2016
Ethics approval number [2] 295003 0
15/07/15/3.03
Ethics committee name [3] 295004 0
Health and Disability Ethics Committees
Ethics committee address [3] 295004 0
Ministry of Health
Freyberg Building
20 Aitken Street
PO Box 5013
Wellington 6011
Ethics committee country [3] 295004 0
New Zealand
Date submitted for ethics approval [3] 295004 0
26/02/2015
Approval date [3] 295004 0
08/05/2015
Ethics approval number [3] 295004 0
15/NTA/25

Summary
Brief summary
This is an observational study of patients who have previously been diagnosed and treated for Microangiopathic Thrombocytopenia (MAT). The study will collect clinical and laboratory data to assess the disease characteristics, laboratory features, treatments, and clinical outcome.
Trial website
www.aptin.org
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 51482 0
Prof Ross Baker
Address 51482 0
Perth Blood Institute,
Hollywood Specialist Centre
3/95 Monash Avenue
Nedlands
WA 6009
Country 51482 0
Australia
Phone 51482 0
+61 892004904
Fax 51482 0
Email 51482 0
ross@aptin.org
Contact person for public queries
Name 51483 0
Dr Jim Tiao
Address 51483 0
Perth Blood Institute,
Hollywood Specialist Centre
3/95 Monash Avenue
Nedlands
WA 6009
Country 51483 0
Australia
Phone 51483 0
+61 93601319
Fax 51483 0
Email 51483 0
jim@aptin.org
Contact person for scientific queries
Name 51484 0
Prof Ross Baker
Address 51484 0
Perth Blood Institute,
Hollywood Specialist Centre
3/95 Monash Avenue
Nedlands
WA 6009
Country 51484 0
Australia
Phone 51484 0
+61 892004904
Fax 51484 0
Email 51484 0
ross@aptin.org

No information has been provided regarding IPD availability
Summary results
No Results